OSE Immunotherapeutics SA announced that the United States Patent and Tradark Office has granted a new patent protecting Tedopi, a therapeutic cancer vaccine treating HLA-A2 positive patients after secondary resistance to PD-1/PD-L1 immune checkpoint inhibitor treatment. The new patent further improves the unique value proposition of Tedopi and provides protection until year 2037 in the US. This US patent recognises the innovation of a multiepitope combination (all peptides included in Tedopi) administered after failure to PD-1/PD -L1 immune checkpoint inhibitor in HLA-A2 positive non-small cell lung cancer (NSCLC) patients.

This further protection for Tedopi, OSE Immunotherapeutics' most advanced late-stage asset, adds significant value to the Company's product portfolio. This patent family, focused on the same targeted population, has been filed internationally in other territories and has already been granted previously in Japan. This population in second line treatment after failure to PD-1-PD-L1 inhibitor treatment, targeted with Tedopi, is estimated to be up to 100,000 patients per year in 7 major markets across the US, Europe, China and Japan.

This estimate is based on HLA-A2-positive patients accounting for about 45% of all NSCLC patients, as well as the large and growing use of anti-PD-L1 therapies and their failure rate.